FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction

FNDC5/irisin improves the therapeutic efficacy of bone marrow-derived mesenchymal stem cells for myocardial infarction

Abstract Background The beneficial functions of bone marrow mesenchymal stem cells (BM-MSCs) decline with decreased cell survival, limiting their therapeutic efficacy for myocardial infarction (MI). Irisin, a novel myokine which is cleaved from its precursor fibronectin type III domain-containing pr...

Full description

Bibliographic Details
Main Authors: Jingyu Deng, Ning Zhang, Yong Wang, Chao Yang, Yabin Wang, Chao Xin, Jinming Zhao, Zhitao Jin, Feng Cao, Zheng Zhang
Format: Article
Language:English
Published: BMC 2020-06-01
Series:Stem Cell Research & Therapy
Subjects:
Bone marrow mesenchymal stem cells (BM-MSCs)
Myocardial infarction (MI)
Fibronectin type III domain-containing protein 5 (FNDC5)
Irisin
Apoptosis
Cell viability
Online Access:http://link.springer.com/article/10.1186/s13287-020-01746-z

Internet

http://link.springer.com/article/10.1186/s13287-020-01746-z

Similar Items